Tscan therapeutics announces upcoming presentations at the 38th society for immunotherapy of cancer annual meeting

Waltham, mass., sept. 27, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming society for immunotherapy of cancer (sitc) annual meeting, being held from november 1-5, 2023, both in san diego, ca and virtually.
TCRX Ratings Summary
TCRX Quant Ranking